BITT will leverage Selexis’ suite of proprietary modular technologies designed to overcome the complex challenges of protein-expression and deliver the high performance research cell banks necessar...
Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,”
CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs.
Under the agreement, Igyxos will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance the program to human trials.
